Fig. 4.

Forest plot of week 12 and 24 model results in csDMARD-IR RA: OR of achieving ≥ 20%, ≥ 50%, or ≥ 70% ACR response versus csDMARD(s). Abbreviations: ACR American College of Rheumatology, csDMARD conventional synthetic disease-modifying antirheumatic drug, csDMARD-IR inadequate response to csDMARD, OR odds ratio, RA rheumatoid arthritis. Notes: ¹Medians and credible intervals for ACR responses were estimated using a random effects multinomial model. The distribution of means and credible intervals was sampled using Monte Carlo methods (150,000 posterior simulations per treatment after 50,000 burn-in, thinning parameter of 10, and 3 chains). ²Due to differences in trial design, ACR responses were used in the 12-week network if reported between 12 and 14 weeks and used in the 24-week network if reported between 24 and 26 weeks. ³JAK combination therapies and monotherapy treatments were analyzed together in the same network